have reported that 7 of 79 patients with relapsed/refractory B-ALL who received CAR-T therapy targeting CD19 or CD19/CD22 experienced severe ICANS, among whom six received systemic steroids as first-line therapy. The gene discussed is CD22; the disease is precursor B-cell acute lymphoblastic leukemia.